儿童癫痫怎么办？快使用呲仑帕奈！

Perampanel is a third-generation new anti-epileptic drug that acts on α-amino-3-hydroxy-5-methyl-4-isoranoxazole propionic acid (AMPA) glutamate receptors and is a highly selective, non-competitive receptor antagonist. It has been used in many countries to treat refractory epilepsy in children, and has shown good effectiveness, safety and tolerability in relevant studies in various countries.

Although parampanel is currently only approved in the United States as a monotherapy or as an add-on treatment for focal epilepsy in children over 4 years of age, some existing studies have shown that parampanel is a safe and effective antiepileptic drug. However, there are relatively few data on the use of parampanel in Chinese children and adolescents. For this reason, China's R&D department is also actively applying for extrapolation indications for phase III clinical trials to 4 to 12 years old and monotherapy. Paraampanel has a promising future.

A retrospective analysis of the medical records of 34 children with refractory epilepsy was performed to evaluate the efficacy and adverse reactions of parampanel by comparing the children's baseline conditions and seizures at weeks 4, 8, 12, 24, 36, and 48 weeks after the addition of parampanel. Results: The average age of the children when parampanel treatment was added was (8.1+4.1) years old, and the male to female sex ratio was 1:1.

After adding valampanel to the treatment, the effective rates at weeks 4, 8, 24, 36, and 48 were 37.5%, 46.7%, 50.0%, 47.4%, 53.8%, and 42.9%, respectively. The incidence of adverse reactions was 32.4%, and the drug retention rate was 88.2%.

It is concluded that parampanel has good efficacy, safety and tolerability in the treatment of refractory epilepsy. Personalized treatment and better baseline seizure control may improve the effectiveness and drug retention of garampanel treatment.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.